Effects of bardoxolone on nuclear factor-erythroid 2-related factor 2 signaling pathway in HCT-116 human colonic cancer cell line: In vitro study

Abstract

Background: Bardoxolone inhibited proliferation and induced apoptosis in vitro in wide types of human cancer cells. It has also been shown to inhibit the growth of tumor in the mice model. Several studies demonstrated that bardoxolone may modulate multiple molecular targets that have a fundamental role in both the development and progression of cancer. Objectives: The aim of this study is to assess the effects of Bardoxolone (CDDO-Me) in the treatment of colonic carcinoma by induction of the nuclear factor erythroid 2-related factor 2 signaling pathway (Nrf2) with regression of tumor markers as compared to other chemotherapeutic agents like 5-fuorouracil. Materials and Methods: Treatment groups are classified into four groups (control, chemotherapy group, bardoxolone, and combination treatment groups). Results: The results revealed that there were significant effects of bardoxolone treatment on cytoplasmic Nrf2 level (P < 0.05) as compared to control group (cancer cells without treatment). Conclusion: Bardoxolone has significant anticancer effects (P < 0.05) in low micrograms concentrations on human colonic cancer cells as compared to control groups.

Keywords

• apoptosis
• bardoxolone
• colon cancer
• hct-116 cell line
• nuclear factor erythroid 2-related factor 2